<DOC>
	<DOCNO>NCT01219920</DOCNO>
	<brief_summary>The purpose study evaluate exposure three active cytotoxic agent ( FOLFOXIRI regimen ) superior term response rate conventional chemotherapy FOLFIRI regimen first-line treatment metastatic colorectal cancer patient .</brief_summary>
	<brief_title>FOLFOXIRI Compared With FOLFIRI Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Survival patient metastatic colorectal cancer correlate proportion patient receive three active drug course disease , proportion patient receive second-line therapy . In sequential strategy , patient progress first-line chemotherapy able receive second-line treatment . Moreover , correlation response rate chemotherapy postchemotherapy radical resection rate metastasis . Therefore , way improve outcome metastatic colorectal cancer patient could administer first-line regimen contain three active agent .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>adenocarcinoma colon rectum unresectable metastatic disease age 18 75 year Eastern Cooperative Oncology Group ( ECOG ) performance status 2 low age 70 year young ECOG performance status 0 age 71 75 year measurable disease accord WHOcriteria leukocyte count least 3,500/mm3 , neutrophil count least 1,500/mm3 , platelet count least 100,000/mm3 serum creatinine 1.3 mg/dL less serum bilirubin le 1.5 mg/dL AST , ALT , alkaline phosphatase 2.5 x normal value less ( &lt; /= 5 liver metastasis ) previous fluoropyrimidinebased adjuvant chemotherapy allow end 6 month random assignment previous palliative chemotherapy metastatic disease previous chemotherapy include irinotecan oxaliplatin symptomatic cardiac disease , myocardial infarction last 24 month uncontrolled arrhythmia active infection inflammatory bowel disease total colectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Phase III</keyword>
	<keyword>FOLFOXIRI</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>